
Champions Oncology CSBR
€ 5.79
-2.6%
Quartalsbericht 2025-Q2
hinzugefügt 15.09.2025
Champions Oncology Langfristiger Schuldenstrom 2011-2026 | CSBR
Langfristiger Schuldenstrom Jährlich Champions Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.47 M | 1.34 M | 1.21 M | 1.05 M | 818 K | 818 K | 438 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.47 M | 438 K | 1.02 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Adagene
ADAG
|
1.18 M | $ 2.62 | 28.82 % | $ 147 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.51 | 7.34 % | $ 8.45 B | ||
|
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 25.92 | -0.86 % | $ 1.26 B | ||
|
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Athira Pharma
ATHA
|
414 K | - | - | $ 269 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
BioLineRx Ltd.
BLRX
|
522 K | $ 3.1 | 4.49 % | $ 908 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
BioNTech SE
BNTX
|
39.5 M | $ 116.27 | -1.86 % | $ 27.2 B | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 235.41 | 2.95 % | $ 5 B | ||
|
BioXcel Therapeutics
BTAI
|
374 K | $ 1.84 | 1.66 % | $ 4.66 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.66 | -1.85 % | $ 16.7 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
7.29 M | $ 67.49 | -3.02 % | $ 9.03 B | ||
|
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 4.51 | 8.41 % | $ 9.81 B | ||
|
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | ||
|
Coherus BioSciences
CHRS
|
1.42 M | $ 2.04 | 28.3 % | $ 192 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
86.4 M | $ 171.89 | -1.1 % | $ 25 B | ||
|
Bio-Path Holdings
BPTH
|
103 K | - | - | $ 100 K | ||
|
BioVie
BIVI
|
74.5 K | $ 1.2 | -3.7 % | $ 1.77 M | ||
|
Baudax Bio
BXRX
|
5.6 M | - | 0.59 % | $ 63 K | ||
|
Calithera Biosciences
CALA
|
1.37 M | - | -10.95 % | $ 876 K | ||
|
Corcept Therapeutics Incorporated
CORT
|
829 K | $ 44.32 | 7.3 % | $ 4.58 B |